Our pioneering research
For more than a decade, JDRF has funded studies to unravel the mysteries of T1D and develop therapeutic interventions to bring the body back to normal after the disease strikes. Each one has added to our understanding of what’s necessary to stop the immune system from destroying insulin-producing islets cells, keep these cells healthy and functional, and restore the body’s normal ability to produce insulin.
Researchers have already shown that the body has the ability to increase insulin production in women with T1D during pregnancy. Now we’re investigating several promising therapeutic strategies, including drugs that form new beta cells, reprogram other cells in the body to become insulin-producing cells and prevent or reverse the loss of beta cell function. Our scientists have also made progress in understanding the mechanisms of the autoimmune attack that causes T1D, opening the way to new immune therapies that will stop the disease in its tracks. JDRF-supported research is leading to the development of a new generation of immune therapies that specifically target the defective components in T1D, leaving the rest of the immune system intact. These and other discoveries have brought us closer to a cure than we imagined a decade ago, and we won’t stop until we find one.